Freenome Stock
HealthTechLooking to sell Freenome stock or options?
Freenome has developed a multi-omics platform that is designed to detect cancer at its early stages using a simple blood draw. The company's unique platform employs a proprietary algorithmic method that strives to revolutionize disease management through systematic early detection and intervention of disease screenings. This allows doctors to treat cancer and other diseases while they are still at manageable stages.
American Cancer Society, CRV, Polaris Partners, RA Capital Management, Pura Vida Investments, HBM Partners, Rock Springs Capital, S28 Capital, dRx Capital Novartis, ArrowMark Partners, AME Cloud Ventures, Roche Venture Fund, ARTIS Ventures, Third Kind Venture Capital, StartX (US), CEC Capital Group, Bedford Bridge, HBM Healthcare Investments, Asset Management Ventures, K50 Ventures, BrightEdge, Perceptive Advisors, Verily Life Sciences, Soleus Capital, Verizon Communications.